Tag : PCI

Latest News

PCI Pharma Services annonce l’acquisition de Bellwyck Pharma Services pour proposer des services mondiaux d’essai clinique au Canada et en Europe continentale

Newsemia
PHILADELPHIE–(BUSINESS WIRE)–PCI Pharma Services (PCI), un chef de file des solutions de chaîne d’approvisionnement pharmaceutique et biopharmaceutique, annonce ce jour l’acquisition de Bellwyck Pharma Services...
Pharma / Biotech

Effect of Smoking Cessation on the Pharmacokinetics and Pharmacodynamics of Clopidogrel after PCI: The Smoking Cessation Paradox Study.

Newsemia
Effect of Smoking Cessation on the Pharmacokinetics and Pharmacodynamics of Clopidogrel after PCI: The Smoking Cessation Paradox Study. Thromb Haemost. 2020 Jan 15;: Authors: Ramotowski...
Latest News

PCI Pharma Services Announces Major Investment to Expand Development and Manufacturing Capabilities at Tredegar, UK Site

Newsemia
PHILADELPHIA–(BUSINESS WIRE)–PCI Pharma Services (PCI), a leading pharmaceutical and biopharmaceutical global outsourcing solutions provider, today announced it has begun an expansion of its Tredegar facility...
Cardiology

Average daily ischemic versus bleeding risk in patients with ACS undergoing PCI: Insights from the BleeMACS and RENAMI registries.

Newsemia
Related Articles Average daily ischemic versus bleeding risk in patients with ACS undergoing PCI: Insights from the BleeMACS and RENAMI registries. Am Heart J. 2019...
Latest News

 Subgroup Analysis of TWILIGHT Trial Patients With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Who Underwent PCI Showed BRILINTA Monotherapy Reduced the Risk of Clinically Relevant Bleeding Compared With Dual Antiplatelet Therapy (DAPT)

Newsemia
WILMINGTON, Del.–(BUSINESS WIRE)–New results from a pre-specified subgroup analysis of the TWILIGHT trial showed that BRILINTA (ticagrelor) monotherapy reduced the risk of clinically relevant bleeding...
Latest News

IDEAL LM study: Biodegradable polymer everolimus-eluting stent is safe, effective for patients undergoing PCI

Newsemia
New data from the IDEAL-LM trial found that a biodegradable polymer everolimus-eluting stent (BP-EES) followed by four months of dual antiplatelet therapy (DAPT) was safe...
Latest News

Shorter duration DAPT after PCI did not increase adverse events in high-bleeding risk patients, finds study

Newsemia
Data from the EVOLVE Short DAPT study found that shortened three-month dual antiplatelet therapy did not increase myocardial infarction or stent thrombosis in high bleeding...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy